Emergency PWAS in Respiratory Infectious Disease

Launched by THE UNIVERSITY OF HONG KONG · Apr 13, 2022

Keywords

ClinConnect Summary

This clinical trial, called the Emergency PanorOmics Wide Association Study (ePWAS), is looking to improve how we understand and diagnose respiratory infections in adults who come to the emergency department. Researchers want to quickly identify and study both known and new types of infections, including viral, bacterial, fungal, and even mixed infections. The goal is to create a special biobank to collect samples and conduct research that could lead to better tests and treatments for these infections.

To participate in this trial, you need to be an adult aged 18 or older who is experiencing symptoms of a recent respiratory infection, like a cough or fever. You should not have been hospitalized in the last 28 days or be part of another clinical trial. If you join, you’ll provide consent and may undergo tests and evaluations to help researchers learn more about your condition. It's important to know that this study aims to help future patients by improving how we detect and treat respiratory infections more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients eligible for enrolment include:
• With reference to previous inclusion criteria are:
• • Adults ≥18 years of age; AND
• • Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\*; AND
• • Informed consent.
• Note: scaRID is defined according to ALL three criteria:
• • 1. Community acquired (not hospitalised for \<28 days); AND
• • 2. Acute infection (defined as symptom onset \<8 days and any ONE of reported fever or chills or aural temperature \>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
• 3. Probable respiratory infection - According to any ONE of:
• • 1. new cough or new sputum production or
• • 2. chest pain or
• • 3. dyspnoea or
• • 4. tachypnoea or
• • 5. abnormal lung examination or
• • 6. respiratory failure; or
• • 7. physician's judgment (presenting with systemic or gastrointestinal symptoms).
• Control subjects will be drawn from two groups:
• • The worried well - adult patients with a National Early Warning Score (NEWS) \<3 and a temperature \<37.5°C.
• • Relatives or accompanying friends with no acute illness.
• Exclusion Criteria:
• • Refusal of consent;
• • Recent hospitalisation (\<28 days);
• • Enrolled in another clinical trial
• • Cellulitis;
• • Skin or orthopaedic infections;
• • Urinary tract infection;
• • Acute abdominal sepsis;
• • Sexual transmitted disease;
• • Human immunodeficiency virus (HIV) infection;
• • Immunocompromised/potential neutropenic fever;
• • Solid organ or haematopoietic stem-cell transplant within the previous 90 days;
• • Active graft-versus-host disease or bronchiolitis obliterans;
• • Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;
• • Stroke;
• • Toxidrome;
• • Non-organic acute psychosis.